Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H21N5O2S2
CAS Number:
Molecular Weight:
331.46
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
nizatidine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
[s]1c(nc(c1)CSCCN\C(=C\[N+](=O)[O-])\NC)CN(C)C
InChI
1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
InChI key
SGXXNSQHWDMGGP-IZZDOVSWSA-N
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Nizatidine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Richard W McCallum et al.
The American journal of the medical sciences, 340(4), 259-263 (2010-10-01)
The aim of the study is to test whether nizatidine delivered via a unique bimodal pulsatile-controlled release system, nizatidine controlled release (CR), accelerates gastric emptying in patients with gastroesophageal reflux disease (GERD). Combined data were analyzed on 39 patients with
Virginia L Stauffer et al.
BMC psychiatry, 9, 12-12 (2009-03-31)
This study focuses on exploring the relationship between changes in appetite or eating behaviors and subsequent weight change for adult patients with schizophrenia or bipolar disorder treated with olanzapine and adjunctive potential weight mitigating pharmacotherapy. The aim is not to
Yoshihiro Wada et al.
Hepato-gastroenterology, 56(91-92), 624-628 (2009-07-23)
Helicobacter pylori (H. pylori) eradication therapy increases acid secretion and promotes the development of gastroesophageal reflux disease (GERD) and reflux esophagitis (RE). Rebound acid hypersecretion develops after the use of proton pump inhibitors (PPI). We examined the clinical necessity of
Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".
Antonio Reis de Sá et al.
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 29(1), 90-90 (2007-04-17)
T Nin et al.
Auris, nasus, larynx, 35(2), 224-229 (2007-12-18)
It was reported that salivary secretion increased in 30 volunteers with administered nizatidine. The aim of the present study was to investigate whether or not nizatidine enhances salivary secretion and improves the function of salivary glands in patients with dry
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service